You searched for: vähipatsientidel (Estniska - Engelska)

vähipatsientidel
in cancer patients

turustamisjärgselt on vähipatsientidel täheldatud ülitundlikkusreaktsioone.
hypersensitivity reactions have been observed in cancer patients in post-marketing experience.

filgrastiimiga ravitud vähipatsientidel on teatatud pseudopodagrast.
pseudogout has been reported in patients with cancer treated with filgrastim.

pseudopodagrast on teatatud vähipatsientidel, keda raviti filgrastiimiga.
pseudogout has been reported in patients with cancer treated with filgrastim.

instanyl oli vähipatsientidel läbimurdevalu ravimisel efektiivsem kui platseebo.
instanyl was more effective than placebo at treating breakthrough pain in cancer patients.

auc oli vähipatsientidel 30% suurem kui tervetel uuringus osalejatel.
the auc was 30 % higher in cancer patients than in healthy subjects.

vähipatsientidel on turustamisjärgselt täheldatud hüpertensiooni (vt lõik 4.4).
hypertension has been observed in cancer patients in post-marketing experience (see section 4.4).

kliiniliste uuringute andmetel esines vähipatsientidel kõiki ülitundlikkusereaktsioone väga sageli.
the frequency of all hypersensitivity reactions was estimated from clinical trial data as very common in cancer patients.

kliiniliste uuringute andmetel esines hüpertensiooni vähipatsientidel ning ka platseeborühmas sageli.
the frequency is estimated from clinical trial data as common in cancer patients and was also common in the placebo groups.

detsitabiini vdss vähipatsientidel on suur, mis viitab ravimi jaotumisele perifeersetes kudedes.
decitabine vdss in cancer patients is large indicating distribution of the drug into peripheral tissues.

inimravimite komitee märkis, et vähipatsientidel on läbimurdevalu raviks vaja kiiretoimelisi valuvaigisteid.
the chmp noted that there was a need for fast-acting pain medicines for breakthrough pain in patients with cancer.

eritumise eriuuringuid vähipatsientidel teostatud ei ole; kuid olemas on andmed transplantatsioonipatsientidel läbi viidud uuringutest.
no specific excretion studies have been undertaken in cancer patients; however, data are available from the studies in transplant patients.

luukao vähenemine muudab luud murdudele vastupidavamaks ning sel viisil saab ennetada luumurdude tekkimist vähipatsientidel, kellel on luumetastaasid.
the reduction of bone loss helps to make bones less likely to break, which is useful in preventing fractures in cancer patients with bone metastases.

luukoe lagundamist peatades muudab ravim luud murdudele vastupidavamaks, millega saab ennetada luumurde luumetastaasidega vähipatsientidel ja osteoporoosiga naistel.
the reduction of bone loss helps to make bones less likely to break, which is useful in preventing fractures in cancer patients with bone metastases and in women with osteoporosis.

ravi ajal sunitiniibiga on kõige sagedamini täheldatud infektsioonideks tavaliselt vähipatsientidel esinevad infektsioonid, nt hingamisteede, kuseteede ja nahainfektsioonid ning sepsis.
the infections observed most commonly with sunitinib treatment are infections typically seen in cancer patients, e.g. respiratory, urinary tract, skin infections and sepsis.

seega on tegemist tromboemboolsete juhtude suurenenud riskiga neil vähipatsientidel, keda ravitakse inimese rekombinantse erütropoetiiniga ja ei saa välistada negatiivset mõju üldisele elulemusele.
there is an increased risk for thromboembolic events in patients with cancer treated with recombinant human erythropoietin and a negative impact on overall survival cannot be excluded.

akynzeo on ravim, mida kasutatakse iivelduse ja oksendamise ennetamiseks täiskasvanud vähipatsientidel, kes saavad keemiaravi (vähiravimid).
akynzeo is a medicine used to prevent nausea (feeling sick) and vomiting in adult patients with cancer who are receiving chemotherapy (medicines to treat cancer).

vähipatsientidel oli keskmine tasakaaluseisundi cmin 200 mg annuse puhul 830 ng/ml (vahemik 200...2400 ng/ml).
the average steady state ctrough for 200 mg was 830 ng/ml (range 200 to 2400 ng/ml) in cancer patients.

pseudopodagrast on teatatud vähipatsientidel, keda raviti filgrastiimiga ja kliiniliste uuringute andmete põhjal on hinnanguline sagedus „aeg-ajalt“.
pseudogout has been reported in cancer patients treated with filgrastim, and the frequency is estimated as uncommon from clinical trial data.

110 vähipatsientidel, kus hemoglobiinisisalduse ravieesmärgiks on < 13 g/ dl, on ebaselge, sest selliste karakteristikutega patsientide arv oli analüüsitud andmekogumis liiga väike.
the extent to which these outcomes might apply to the administration of recombinant human erythropoietin to patients with cancer, treated with chemotherapy to achieve haemoglobin concentrations less than 13 g/ dl, is unclear because few patients with these characteristics were included in the data reviewed.